Name | Title | Contact Details |
---|---|---|
Craig Guinasso |
Associate Director - Information Security | Profile |
Dave Green |
Senior Director of Information Technology | Profile |
Mike Vedda |
Chief Information Officer | Profile |
We are a clinical stage development and licensing biotechnology company focused on leveraging our Pfenex Expression Technology™ platform to develop and improve protein therapies for unmet patient needs.
BioClin Therapeutics, Inc. is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. Our lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development. B-701 has been tested in two Phase 1 clinical trials involving 40 patients and demonstrated potential efficacy in patients with metastatic bladder cancer who were receiving it as 2nd line therapy.
Codex DNA is home to Gibson Assembly, and pioneering synthetic DNA/gene synthesis hardware, including the BioXp, the world’s first DNA printer. Our mission is to empower scientific researchers in both academic and commercial settings with the materials...
Gyroscope Therapeutics is a clinical-stage gene therapy company developing gene therapy beyond rare disease to treat diseases of the eye that cause vision loss and blindness. The company was acquired by Novartis, a leading global medicines company, in February 2022.
ON TARGET LABORATORIES discovers and develops fluorescent markers to target and illuminate cancer during surgery so it can be removed more completely.